

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

31 May 2026

### Evaluation of the effectiveness of complementary therapy with *Portulaca oleracea* capsule on the clinical symptoms of outpatients with COVID-19

#### Protocol summary

##### Study aim

Evaluation of the effectiveness of *Portulaca Oleracea* extract on the clinical COVID-19

##### Design

Clinical trial with control group, with parallel groups, double-blind, randomized, block method, phase 3 on 140 patients. For randomization, the balanced block method is used using 4 blocks using SAS software.

##### Settings and conduct

Patients who have Covid 19 (RT-PCR confirmation) and have referred to the 16-hour treatment centers of Mashhad University of Medical Sciences and have the inclusion criteria, are included in the study. After obtaining informed consent, patients are randomly divided into 2 groups. The placebo group will receive the usual treatments and the placebo capsule and the intervention group, in addition to the usual treatments, will receive an oral capsule of *portulaca oleracea* extract at a dose of 600 mg (divided into a dose of 300 mg twice a day) for 2 weeks. Clinical and laboratory signs and symptoms will be studied, evaluated and compared before and after the intervention in both groups. The recovery time of symptoms including shortness of breath, anorexia, and oxygen saturation of the blood will be compared. The two groups are matched and equalized in terms of age, comorbidities, severity of Covid involvement, and clinical symptoms.

##### Participants/Inclusion and exclusion criteria

Outpatients with PCR-approved Covid-19 with 90% oxygen have no underlying disease and are not pregnant or breastfeeding

##### Intervention groups

In the intervention group, 600 mg of *Portulaca Oleracea* extract is given to patients along with common drugs. Control group (placebo) receive only common drugs with placebo.

##### Main outcome variables

Improvement of clinical symptoms (fever, cough and myalgia) and paraclinical (time of normalization of

lymphopenia and CRP)

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20190303042889N1**

Registration date: **2021-03-30, 1400/01/10**

Registration timing: **prospective**

Last update: **2021-03-30, 1400/01/10**

Update count: **0**

##### Registration date

2021-03-30, 1400/01/10

##### Registrant information

##### Name

Zahra Habibian

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 51 3221 4363

##### Email address

habibiannezhadz971@mums.ac.ir

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-05-05, 1400/02/15

##### Expected recruitment end date

2021-09-21, 1400/06/30

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

Evaluation of the effectiveness of complementary therapy with Portulaca oleracea capsule on the clinical symptoms of outpatients with COVID-19

### Public title

Evaluation of the effectiveness of complementary therapy with Portulaca oleracea capsule on the clinical symptoms of outpatients with COVID-19

### Purpose

Treatment

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Outpatient with COVID-19 Age 18-60 years Patient satisfaction Being alert and lacking organ damage Confirmation of RT-PCR test for SARS-CoV-2 Blood saturated oxygen content more than 90%

#### Exclusion criteria:

Pregnant and lactating women comorbidity End stage Patient

### Age

From **18 years** old to **60 years** old

### Gender

Both

### Phase

3

### Groups that have been masked

- Participant
- Outcome assessor

### Sample size

Target sample size: **70**

### Randomization (investigator's opinion)

Randomized

### Randomization description

In order to allocate individuals in the two groups of 70 people studied, the blocking method will be used and for this purpose, among the given probabilities, four blocks have been randomly selected, which include: 1- ABBA- 2- AABB- 3- BABA-4-BBAA and each patient visited in one of the first or second groups will be entered in the blocks mentioned above, respectively. After completing the four blocks, the allocation of individuals in the study groups starts again from block one to complete the 140 samples required in the study.

### Blinding (investigator's opinion)

Double blinded

### Blinding description

This study is a clinical trial with two groups of control and intervention in which placebo is used. For blinding the study, drug form would be similar in two groups and the allocation of individuals is based on the block randomization method. The prescribing physician and the patient will not know the type of capsule that was the medication or the placebo.

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Ethics committee of Mashhad University of Medical Sciences

##### Street address

Mashhad University of Medical Sciences, Azadi Square, Mashhad

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9177948564

#### Approval date

2021-02-27, 1399/12/09

#### Ethics committee reference number

IR.MUMS.REC.1399.646

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19

#### ICD-10 code

U07.1

#### ICD-10 code description

COVID-19

## Primary outcomes

### 1

#### Description

Improvement time of clinical manifestation based on questionnaire

#### Timepoint

The beginning of the intervention & day 14

#### Method of measurement

questionnaire

### 2

#### Description

Normalization of CRP and lymphopenia

#### Timepoint

The beginning of the intervention & day 14

#### Method of measurement

laboratory

## Secondary outcomes

empty

## Intervention groups

### 1

#### Description

Intervention group: Receive common treatments and 300 mg of Portulaca Oleracea extract capsules 2 times a day for 7 days

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Receive common treatments and placebo capsules

#### Category

Placebo

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

16-hour corona centers

##### Full name of responsible person

SeyedeZahra Habibiannezhad

##### Street address

Mashhad university of medical science, Azadi square

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9177948564

##### Phone

+98 51 3800 2000

##### Email

habibiannezhadz971@mums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Taphaghodi, Mohsen

##### Street address

Deputy of Research and Technology, Ghorashi Building, next to Hoveyze Cinema, University Street

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9138813944

##### Phone

+98 51 3841 1538

##### Email

tafaghodim@mums.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Mashhad University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

empty

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Seyedeh Zahra HabibianNejad

##### Position

Family Medicine Student

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Family Physician

##### Street address

Mashhad University of Medical Sciences, Azadi square

##### City

Mashhad

##### Province

Razavi Khorasan

##### Postal code

9136964795

##### Phone

98 51 38049

##### Email

Habibiannezhadz971@mums.ac.ir

## Person responsible for scientific inquiries

#### Contact

##### Name of organization / entity

Mashhad University of Medical Sciences

##### Full name of responsible person

Seyedeh Zahra HabibianNejad

##### Position

Family Medicine Student

##### Latest degree

Medical doctor

##### Other areas of specialty/work

Family Physician

##### Street address

Azadi square, Mashhad University of Medical Science

**City**

Mashhad

**Province**

Razavi Khorasan

**Postal code**

9136964795

**Phone**

98 51 38049

**Email**

Habibiannezhadz971@mums.ac.ir

**Postal code**

9136964795

**Phone**

98 51 38049

**Email**

Habibiannezhadz971@mums.ac.ir

**Person responsible for updating data****Contact****Name of organization / entity**

Mashhad University of Medical Sciences

**Full name of responsible person**

Seyedeh Zhahra HabibianNejad

**Position**

Family Medicine Student

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Family Physician

**Street address**

Azadi square, Mashhad University of Medical Science

**City**

Mashhad

**Province**

Razavi Khorasan

**Sharing plan****Deidentified Individual Participant Data Set (IPD)**

Undecided - It is not yet known if there will be a plan to make this available

**Study Protocol**

Undecided - It is not yet known if there will be a plan to make this available

**Statistical Analysis Plan**

Undecided - It is not yet known if there will be a plan to make this available

**Informed Consent Form**

Undecided - It is not yet known if there will be a plan to make this available

**Clinical Study Report**

Undecided - It is not yet known if there will be a plan to make this available

**Analytic Code**

Undecided - It is not yet known if there will be a plan to make this available

**Data Dictionary**

Undecided - It is not yet known if there will be a plan to make this available